Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times Arkansas.
Press releases published on April 2, 2025
ProMOS Adopts Silvaco Victory TCAD Solution for the Development of Next-Gen Silicon Photonics Devices
GlobeNewswire
·
April 2, 2025
SANTA CLARA, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or the “Company”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and …
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy …
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 2, 2025
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and …
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, …
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer …
Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Grove AI, pioneer in life science automation using agentic AI, today announced the formation of its inaugural Advisory Board. Comprised of prominent leaders from pharmaceutical and technology sectors, the …
Moringa: Learn Why These Moringa Powder Supplements Are Transforming Energy, Immunity, and Overall Health
GlobeNewswire
·
April 2, 2025
LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) -- Moringa Oleifera, often called the “Miracle Tree,” is rapidly gaining recognition in the U.S. as a superfood for its remarkable health benefits. From boosting daily energy levels to fortifying immune support, …
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
·
April 2, 2025
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of …
Building on Past Success, Incident IQ Names Ryan Zeek as Chief Financial Officer
GlobeNewswire
·
April 2, 2025
ATLANTA, April 02, 2025 (GLOBE NEWSWIRE) -- Incident IQ, the leading workflow management platform built specifically to streamline K-12 school districts, has announced the appointment of Ryan Zeek as Chief Financial Officer. Ryan steps into the role after …
SchoolAI Secures $25 Million to Help Teachers and Schools Reach Every Student
GlobeNewswire
·
April 2, 2025
LEHI, Utah, April 02, 2025 (GLOBE NEWSWIRE) -- SchoolAI, a leading AI platform for teaching and learning, today announced it has closed $25 million in Series A funding to tackle education’s fundamental challenge: helping teachers provide personalized …
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
GlobeNewswire
·
April 2, 2025
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, …
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of …
Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, and a leader …
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, ainsi qu'un acteur clé sur le …
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, …
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer …
Lantronix Named to CRN 2025 Internet of Things 50 List
GlobeNewswire
·
April 2, 2025
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced it has been recognized on the 2025 Internet of Things (IoT) 50 …
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
GlobeNewswire
·
April 2, 2025
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) …
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
GlobeNewswire
·
April 2, 2025
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., …
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
GlobeNewswire
·
April 2, 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 …